8-K current report · filed Nov 18, 2026

Tempus AI Inc (TEM) 8-K Current Report: November 18, 2026

Item 1.01TEM overview

Short answer

Tempus AI Inc (TEM) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). AstraZeneca committed $200 million through 2031, providing Tempus visibility into a major multi-year revenue stream.

Tempus AI Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • AstraZeneca committed $200 million through 2031, providing Tempus visibility into a major multi-year revenue stream
  • Annual target spend $40 million across existing and future Tempus products and services
  • Minimum annual fees of $32 million, supporting baseline demand but not guaranteeing full $40 million targets
  • Agreement extends MSA through December 31, 2031, with a potential one-year extension for commitment shortfalls
  • AstraZeneca retains convenience termination rights, but must cover any remaining commitment shortfall upon termination

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tempus AI Inc 8-K filings

Get the next TEM 8-K as it lands

Follow TEM for push alerts, or ask the research agent what this filing means.